Co., CEO Who Defended 'Pharma Bro' Reach $50M FCA Deal
A New Jersey drugmaker and its CEO agreed to pay up to $50 million to settle allegations that the company purposely underpaid Medicaid drug rebates for its bladder infection drug after...To view the full article, register now.
Already a subscriber? Click here to view full article